论文部分内容阅读
未来两三年内,中国医药流通体制将发生重大变化,应尽快批准民营企业经营医药批发和社会化医药配送,并推动医药流通企业进入资本市场。这是有关部门官员和业界专家在日前举行的“中国医药流通体制改革与WTO”座谈会上形成的共识。 中国医药工业年产值已近2000亿元人民币,但医药流通体制改革长期滞后,医药产品经营单位仅限于国有和集体性质的企业。尽管国家医药主管部门做了大量工作,
In the next two to three years, major changes will take place in China’s pharmaceutical distribution system. Private enterprises should be authorized to operate pharmaceutical wholesale and socialized medicine distribution as soon as possible, and pharmaceutical distribution companies should be encouraged to enter the capital market. This is the consensus reached by officials of the relevant departments and industry experts at the forum held recently on the reform of China’s pharmaceutical distribution system and the WTO. The annual output value of China’s pharmaceutical industry is nearly 200 billion yuan. However, the reform of the pharmaceutical circulation system has been lagging behind for a long time. The pharmaceutical product business units are limited to state-owned and collective enterprises. Although the national competent medical department has done a lot of work,